First human test of new hope for Tough-to-Treat blood cancer

NCT ID NCT07409246

Not yet recruiting Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test a new drug called ABBV-438 for advanced multiple myeloma, a blood cancer that has returned or stopped responding to other treatments. The main goal is to find a safe dose and see how the body processes the drug. About 127 adults worldwide who have already tried at least three other types of therapy will receive the drug by IV infusion to help researchers learn if it is safe and effective.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.